Profile
| Metric | Value |
|---|---|
| Full Name | Altimmune, Inc. |
| Ticker | NASDAQ: ALT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | altimmune.com |
| Employees | 59 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $4.19 | |
| Price, 1D Change | +5.81% | |
| Market Cap | $437M | |
| TTM Dividend Yield | - | |
| PE Ratio | - | |
| Beta | 1.36 | |
| Revenue | $20K | |
| Revenue, 1Y Change | -95.31% | |
| EPS | -$1.34 | |
| EPS, 1Y Change | +19.40% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | $873.01 | |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:30 | |
| Next Split | N/A | N/A |
| Last Ticker Change | PIP | |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.34 | |
| EPS Estimate | -$0.98 | |
| EPS Est. Change | +27.02% | |
| Revenue | $20.00K | |
| Revenue Estimate | $3,890.00 | |
| Revenue Est. Change | -80.55% | |
| Current Price | $4.19 | |
| Price Target | - | $19.00 |
| Price Tgt. Change | - | +353.46% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$1.47 | -$1.66 | -13.00% | |
| -$1.34 | -$1.34 | +0.39% | |
| -$0.98 | N/A | +27.02% | |
| -$1.34 | N/A | -0.09% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $340.00K | $426.00K | +25.29% | |
| $3,120.00 | $20.00K | +541.03% | |
| $3,890.00 | N/A | -80.55% | |
| $2,500.00 | N/A | -87.50% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -42.68% | |
| Price, 3Y | -70.68% | |
| Market Cap, 1Y | -17.34% | |
| Market Cap, 3Y | -37.82% | |
| Revenue, 1Y | -95.31% | |
| Revenue, 3Y | -99.55% | |
| EPS, 1Y | +19.40% | |
| EPS, 3Y | +43.07% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $4.19 | |
| SMA 200 | $4.55 | |
| SMA 200 vs Price | +8.69% | |
| SMA 50 | $4.47 | |
| SMA 50 vs Price | +6.79% | |
| Beta | 1.36 | |
| ATR | $0.36 | |
| 14-Day RSI | 47.45 | |
| 10-Day Volatility | 101.75% | |
| 1-Year Volatility | 90.61% |
Dividends
| Metric | Date | Value |
|---|---|---|
| Last Paid | $873.01 | |
| Upcoming | N/A | N/A |
| Dividend Yield | - | |
| Total Dividend | - | |
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $20.00K | |
| EPS | -$1.34 | |
| Gross Profit | -$218.00K | |
| Gross Margin | -1,090.00% | |
| Operating Profit | -$103.17M | |
| Operating Margin | -515.86% | |
| Net Income | -$95.06M | |
| Net Margin | -475.30% | |
| EBITDA | -$94.81M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| 13.11 | ||
| 13.11 | ||
| - | ||
| 3 | ||
| 9.80 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 21.86K | ||
| 2.36 | ||
| -2.68 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $123.51M | |
| $36.93M | ||
| $139.31M | ||
| $137.25M | ||
| $15.80M | ||
| $10.47M | ||
| Total Debt | $1.68M | |
| $279.00K | ||
| $211.00K |
Expenses
| Metric | Date | Value |
|---|---|---|
| $103.19M | ||
| $103.19M | ||
| $238.00K | ||
| $20.97M | ||
| $238.00K | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$79.85M | ||
| -$28.39M | ||
| $10.04M | ||
| Capex | $0.00 | |
| -$79.85M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Citizens | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| UBS | → | |
| HC Wainwright & Co. | → | |
| B. Riley Securities | → | |
| JMP Securities | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Citizens Capital Markets | → |
Analyst sentiment
Institutional ownership
Screeners with ALT
Data Sources & References
- ALT Official Website altimmune.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1326190/000132619025000064/0001326190-25-000064-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1326190/000132619025000015/0001326190-25-000015-index.htm
- ALT Profile on Yahoo Finance finance.yahoo.com/quote/ALT
- ALT Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/alt
FAQ
What is the ticker symbol for Altimmune, Inc.?
The ticker symbol for Altimmune, Inc. is NASDAQ:ALT
Does Altimmune, Inc. pay dividends?
No, Altimmune, Inc. does not pay dividends
What sector is Altimmune, Inc. in?
Altimmune, Inc. is in the Healthcare sector
What industry is Altimmune, Inc. in?
Altimmune, Inc. is in the Biotechnology industry
What country is Altimmune, Inc. based in?
Altimmune, Inc. is headquartered in United States
When did Altimmune, Inc. go public?
Altimmune, Inc. initial public offering (IPO) was on May 26, 2017
Is Altimmune, Inc. in the S&P 500?
No, Altimmune, Inc. is not included in the S&P 500 index
Is Altimmune, Inc. in the NASDAQ 100?
No, Altimmune, Inc. is not included in the NASDAQ 100 index
Is Altimmune, Inc. in the Dow Jones?
No, Altimmune, Inc. is not included in the Dow Jones index
When was Altimmune, Inc. last earnings report?
Altimmune, Inc.'s most recent earnings report was on November 6, 2025
When does Altimmune, Inc. report earnings?
The next expected earnings date for Altimmune, Inc. is February 26, 2026